- |||||||||| sitravatinib (MGCD516) / BeiGene, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial completion, Enrollment change, Trial completion date: Study of Sitravatinib, Nivolumab and Ipilimumab in Advanced or Metastatic Clear-Cell Renal Cell Carcinoma or Other Solid Malignancies (clinicaltrials.gov) - Jun 4, 2024
P1, N=22, Completed,
Active, not recruiting --> Completed | N=92 --> 22 | Trial completion date: Feb 2024 --> Jun 2023
- |||||||||| Journal: Management of cytomegalovirus reactivation in patient with immunotherapy-induced gastritis. (Pubmed Central) - Jun 4, 2024
We present the case of a 52-year-old woman diagnosed with stage IV clear cell renal cell carcinoma who received combination of surgery and systemic therapy with nivolumab (anti-PD1) and ipilimumab (anti-CTLA-4)...CMV viral load by quantitative PCR in plasma was 2,000 IU/mL so intravenous ganciclovir was prescribed...Second-line treatment with Anti-TNF was performed using a single-dose regimen of intravenous infliximab 5 mg/Kg. Finally, the patient presented a clinical and endoscopic response and a negative CMV DNA test in the blood after completing the antiviral treatment.
- |||||||||| Retrospective data, Review, Journal, HEOR, Checkpoint inhibition, Cost-effectiveness, Cost effectiveness, Metastases: First-line treatments for advanced non-squamous non-small cell lung cancer with immune checkpoint inhibitors plus chemotherapy: a systematic review, network meta-analysis, and cost-effectiveness analysis. (Pubmed Central) - Jun 3, 2024
At a WTP threshold of $38,017/QALY, AteC had the highest probability of cost-effectiveness (94%). Although PembroC has the optimal efficacy, NivoIpiC and AteC were the most favorable treatments in terms of cost-effectiveness for patients with advanced non-squamous NSCLC from the US and Chinese perspectives, respectively.
- |||||||||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial completion, Trial completion date: Nivolumab and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma (clinicaltrials.gov) - Jun 3, 2024
P2, N=67, Completed,
Although PembroC has the optimal efficacy, NivoIpiC and AteC were the most favorable treatments in terms of cost-effectiveness for patients with advanced non-squamous NSCLC from the US and Chinese perspectives, respectively. Active, not recruiting --> Completed | Trial completion date: Nov 2025 --> May 2024
- |||||||||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Journal, Checkpoint inhibition: Elevated CK from immune checkpoint inhibitor- related hypophysitis: a case report. (Pubmed Central) - May 31, 2024
Here we report a case of ICI-related hypophysitis related myopathy that was initially misdiagnosed as ICI-associated inflammatory myositis. This case illustrates the importance of considering a wide differential when assessing hyperCKemia in the setting of ICI use.
- |||||||||| Clinical, Journal: The role of immunotherapy in urological cancers. (Pubmed Central) - May 31, 2024
Considering ongoing randomized clinical trials, immunotherapeutic agents promise to transform the uro-oncology field significantly. In this review, we aimed to summarize the role of immunotherapy in urothelial, renal and prostate cancer in the light of randomized clinical trials.
- |||||||||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment closed, Enrollment change, Trial primary completion date: Hepatic Ablation of Melanoma Metastases to Enhance Immunotherapy Response, a Phase I Clinical Trial (HAMMER I) (clinicaltrials.gov) - May 31, 2024
P1, N=2, Active, not recruiting,
In this review, we aimed to summarize the role of immunotherapy in urothelial, renal and prostate cancer in the light of randomized clinical trials. Recruiting --> Active, not recruiting | N=18 --> 2 | Trial primary completion date: Jun 2024 --> Jun 2023
- |||||||||| Review, Journal, PD(L)-1 Biomarker, IO biomarker: An updated review of immunotherapy in esophageal cancer: PD-L1 footprint. (Pubmed Central) - May 30, 2024
Therefore, immunotherapy for esophageal cancer targeting the PD-1/PD-L1 pathway has shown a remarkable correlation with cancer care. This study presents a comprehensive review of the latest findings related to immunotherapy in esophageal cancer.
- |||||||||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Retrospective data, Journal, Metastases: Prognostic impact of FAN score in patients receiving nivolumab plus ipilimumab for metastatic renal cell carcinoma. (Pubmed Central) - May 30, 2024
In multivariable Cox proportional hazard analyses, FAN score???2 was a significant predictor of poor PFS2 (vs. FAN score 0, HR: 2.43, 95% CI 1.21-4.87, P?=?0.01), poor CSS (vs. FAN score 0, HR: 2.71, 95% CI 1.13-6.47, P?=?0.02) and poor OS (vs. FAN score 0, HR: 2.42, 95% CI 1.11-5.25, P?=?0.02). High pre-treatment FAN score could be a significant independent predictor of poor prognosis in patients receiving nivolumab plus ipilimumab for metastatic RCC.
- |||||||||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial completion date, Trial termination: INFLUENCE: Immunotherapy Combined With Radiation and Influenza Vaccine for Pancreatic Cancer. (clinicaltrials.gov) - May 28, 2024
P2, N=19, Terminated,
Trial completion date: Feb 2024 --> Jan 2027 Trial completion date: Apr 2024 --> Oct 2023 | Active, not recruiting --> Terminated; Based on the precpecified interim analysis the predictive probability was below 10% for the prespecified endpoint.
- |||||||||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment closed, Trial completion date, Checkpoint inhibition: LAPTOP: Nivolumab, Ipilimumab and Chemoradiation in Pancreatic Cancer. (clinicaltrials.gov) - May 28, 2024
P1/2, N=40, Active, not recruiting,
Trial completion date: Apr 2024 --> Oct 2023 | Active, not recruiting --> Terminated; Based on the precpecified interim analysis the predictive probability was below 10% for the prespecified endpoint. Recruiting --> Active, not recruiting | Trial completion date: Jun 2024 --> Dec 2024
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Journal, HEOR, Real-world evidence, PD(L)-1 Biomarker, IO biomarker, Real-world, Metastases: Real-world evidence of efficacy of pembrolizumab plus chemotherapy and nivolumab plus ipilimumab plus chemotherapy as initial treatment for advanced non-small cell lung cancer. (Pubmed Central) - May 26, 2024
In real-world practice, CP demonstrated superior PFS compared with CNI. These findings can inform treatment selection in advanced NSCLC.
- |||||||||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Journal, Metastases: Usage of nivolumab and ipilimumab for recurrent or advanced malignant vaginal melanoma: a two-case series. (Pubmed Central) - May 26, 2024
Both patients had immune-related adverse events coinciding with periods of high therapeutic efficacy of immune checkpoint inhibitors. Neoadjuvant therapy with immune checkpoint inhibitors and radiotherapy for immune checkpoint inhibitor resensitization may effectively treat advanced or recurrent vaginal melanoma.
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Journal, Tumor mutational burden, PD(L)-1 Biomarker, IO biomarker, Metastases: Efficacy of Pembrolizumab vs. Nivolumab Plus Ipilimumab in Metastatic NSCLC in Relation to PD-L1 and TMB Status. (Pubmed Central) - May 25, 2024
Corresponding to patients with low PDL-1 less than 1% and low TMB (0-5), the median overall survival (mOS) was 16 (p = 0.18), and 15 months (p = 0.22), patients with medium PDL-1 (1-49%) and medium TMB (5-10), the mOS was 15 (p = 0.18) and 16 months (p = 0.22), patients with high PDL-1 (>50) and high TMB (>10), the mOS was 24 (p = 0.18) and 21 (p = 0.22) months. This study represents the largest academic RWD dataset concerning PD-L1 and TMB status in patients with locally advanced and metastatic NSCLC.
- |||||||||| Bavencio (avelumab) / EMD Serono, Keytruda (pembrolizumab) / Merck (MSD), Yervoy (ipilimumab) / BMS
Review, Journal, Checkpoint inhibition, Immunomodulating: Immunomodulatory Precision: A Narrative Review Exploring the Critical Role of Immune Checkpoint Inhibitors in Cancer Treatment. (Pubmed Central) - May 25, 2024
This article comprehensively reviews the classification, mechanism of action, application, and combination strategies of ICIs in various cancers and discusses their current limitations. Our objective is to contribute to the future development of more effective anticancer drugs targeting immune checkpoints.
- |||||||||| Opdivo (nivolumab) / BMS, NP-101 / Novatek Pharma, Yervoy (ipilimumab) / BMS
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date: EP-NECAs: NP-101 (TQ Formula) With Nivolumab and Ipilimumab in Advanced or Metastatic Extra-pulmonary Neuroendocrine Carcinomas (clinicaltrials.gov) - May 24, 2024
P1, N=15, Active, not recruiting,
There was minimal activity with ICI therapy in patients with CDK12-altered mCRPC. Recruiting --> Active, not recruiting | N=10 --> 15 | Trial completion date: Apr 2024 --> Apr 2026 | Trial primary completion date: Apr 2024 --> Oct 2024
- |||||||||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Enrollment closed, Checkpoint inhibition: Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma (clinicaltrials.gov) - May 23, 2024
P2, N=30, Active, not recruiting,
Recruiting --> Active, not recruiting | N=10 --> 15 | Trial completion date: Apr 2024 --> Apr 2026 | Trial primary completion date: Apr 2024 --> Oct 2024 Recruiting --> Active, not recruiting
- |||||||||| Trial completion date, Trial primary completion date, Checkpoint inhibition, IO biomarker: Exercise to Boost Response to Checkpoint Blockade Immunotherapy (clinicaltrials.gov) - May 22, 2024
P1, N=32, Recruiting,
Recruiting --> Active, not recruiting Trial completion date: May 2024 --> Sep 2024 | Trial primary completion date: May 2024 --> Sep 2024
- |||||||||| Yervoy (ipilimumab) / BMS
Review, Journal, Checkpoint inhibition, Checkpoint block: Advancing cancer immunotherapy through siRNA-based gene silencing for immune checkpoint blockade. (Pubmed Central) - May 21, 2024
The recent emergence of immune checkpoint blockade (ICB) therapies, particularly following the first approval of cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitors like ipilimumab, has led to significant growth in cancer immunotherapy...The important point is that when used in combination with siRNA-based ICB therapy, the synergistic effect of traditional therapies is strengthened, improving host immune surveillance and therapeutic outcomes. Conclusively, we discuss the insights into innovative and effective cancer immunotherapeutic strategies based on RNA interference (RNAi) technology utilizing siRNA and nanocarriers as a novel approach in ICB cancer immunotherapy.
- |||||||||| Tevimbra (tislelizumab) / BeiGene
Journal: Tislelizumab (Tevimbra) for esophageal cancer. (Pubmed Central) - May 21, 2024
Conclusively, we discuss the insights into innovative and effective cancer immunotherapeutic strategies based on RNA interference (RNAi) technology utilizing siRNA and nanocarriers as a novel approach in ICB cancer immunotherapy. No abstract available
- |||||||||| Enweida (envafolimab) / 3DMed, Ascletis, Yervoy (ipilimumab) / BMS
Enrollment closed, Trial completion date, Trial primary completion date, Combination therapy, Metastases: ENVASARC: Envafolimab And Envafolimab With Ipilimumab In Patients With Undifferentiated Pleomorphic Sarcoma Or Myxofibrosarcoma (clinicaltrials.gov) - May 20, 2024
P2, N=207, Active, not recruiting,
Trial completion date: Dec 2024 --> Jun 2025 | Trial primary completion date: Dec 2024 --> Jun 2025 Recruiting --> Active, not recruiting | Trial completion date: Jun 2024 --> Oct 2024 | Trial primary completion date: Jun 2024 --> Oct 2024
- |||||||||| LN-145-S1 / Iovance Biotherap, LN-145 / Iovance Biotherap
Trial completion date, Trial primary completion date: NCI-2018-00918: LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas (clinicaltrials.gov) - May 20, 2024
P2, N=30, Active, not recruiting,
Recruiting --> Active, not recruiting | Trial completion date: Jun 2024 --> Oct 2024 | Trial primary completion date: Jun 2024 --> Oct 2024 Trial primary completion date: Jun 2024 --> Jun 2025 | Trial completion date: Jun 2024 --> Jun 2025
- |||||||||| BMS-986301 / BMS, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial completion, Enrollment change, Monotherapy: An Investigational Immunotherapy Study of BMS-986301 Alone or in Combination With Nivolumab, and Ipilimumab in Participants With Advanced Solid Cancers (clinicaltrials.gov) - May 19, 2024
P1, N=54, Completed,
Recruiting --> Active, not recruiting Active, not recruiting --> Completed | N=190 --> 54
- |||||||||| TP-1454 / Sumitomo Pharma
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date: Phase 1 Study of Oral TP-1454 (clinicaltrials.gov) - May 19, 2024
P1, N=31, Active, not recruiting,
Active, not recruiting --> Completed | N=190 --> 54 Recruiting --> Active, not recruiting | N=50 --> 31 | Trial completion date: Dec 2025 --> Oct 2024 | Trial primary completion date: Sep 2025 --> Oct 2024
- |||||||||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Biomarker, Journal, PD(L)-1 Biomarker, IO biomarker, Metastases: Validation of the Lung Immune Prognostic Index (LIPI) as a prognostic biomarker in metastatic renal cell carcinoma. (Pubmed Central) - May 19, 2024
Recruiting --> Active, not recruiting | N=50 --> 31 | Trial completion date: Dec 2025 --> Oct 2024 | Trial primary completion date: Sep 2025 --> Oct 2024 Pretreatment-LIPI correlated with worse survival outcomes in mRCC treated with either ICI or antiangiogenic therapy, confirming LIPI's prognostic role in mRCC irrespective of systemic treatment used.
- |||||||||| Disseminated Intravascular Coagulation Associated with Immune Checkpoint Inhibitors: Analysis of FAERS Database (Exhibition Hall) - May 17, 2024 - Abstract #ISTH2024ISTH_879;
Nivolumab accounted for most cases (205 cases, ROR 12.4, 95% CI 10.8-14.3), followed by Pembrolizumab (128 cases, ROR 9.1, 95% CI 7.6-10.8), Ipilimumab (97 cases, ROR 14.4, 95% CI 11.8-17.6), and Atezolizumab (70 cases, ROR 9.8, 95% CI 7.7-12.4). The distribution of cases was 56.9% in males and 37.1% in females.
- |||||||||| Journal, Metastases: Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update. (Pubmed Central) - May 15, 2024
A cautious approach to systemic therapy is recommended for patients with Child-Pugh class B advanced HCC. Further guidance on choosing between options is included within the guideline.Additional information is available at www.asco.org/gastrointestinal-cancer-guidelines.
|
